$9.22 Million in Sales Expected for Xenon Pharmaceuticals Inc. (NASDAQ:XENE) This Quarter

Wall Street brokerages expect Xenon Pharmaceuticals Inc. (NASDAQ:XENEGet Rating) to announce $9.22 million in sales for the current quarter, according to Zacks. Five analysts have made estimates for Xenon Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $6.75 million and the highest estimate coming in at $15.00 million. Xenon Pharmaceuticals reported sales of $4.36 million in the same quarter last year, which would suggest a positive year-over-year growth rate of 111.5%. The firm is expected to issue its next earnings report on Monday, January 1st.

On average, analysts expect that Xenon Pharmaceuticals will report full-year sales of $22.02 million for the current financial year, with estimates ranging from $6.80 million to $57.50 million. For the next financial year, analysts forecast that the company will post sales of $28.00 million, with estimates ranging from $16.00 million to $40.00 million. Zacks’ sales averages are an average based on a survey of research firms that cover Xenon Pharmaceuticals.

Xenon Pharmaceuticals (NASDAQ:XENEGet Rating) last announced its quarterly earnings data on Tuesday, March 1st. The biopharmaceutical company reported ($0.57) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.47) by ($0.10). The business had revenue of $3.74 million during the quarter, compared to the consensus estimate of $4.20 million. Xenon Pharmaceuticals had a negative return on equity of 24.14% and a negative net margin of 425.88%. During the same period in the prior year, the firm earned ($0.34) EPS.

XENE has been the topic of a number of research reports. TheStreet raised shares of Xenon Pharmaceuticals from a “d+” rating to a “c” rating in a research report on Monday, March 14th. Wedbush restated an “outperform” rating on shares of Xenon Pharmaceuticals in a report on Wednesday, March 2nd. William Blair restated an “outperform” rating on shares of Xenon Pharmaceuticals in a report on Wednesday, March 2nd. Finally, StockNews.com initiated coverage on shares of Xenon Pharmaceuticals in a report on Thursday, March 31st. They set a “sell” rating on the stock. Two analysts have rated the stock with a sell rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $44.00.

In other Xenon Pharmaceuticals news, EVP Sherrington Robin sold 21,710 shares of the company’s stock in a transaction on Friday, March 4th. The shares were sold at an average price of $30.50, for a total value of $662,155.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Simon N. Pimstone sold 31,086 shares of the company’s stock in a transaction on Monday, March 7th. The shares were sold at an average price of $30.50, for a total transaction of $948,123.00. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 94,974 shares of company stock worth $2,899,047. 7.48% of the stock is owned by corporate insiders.

Several large investors have recently added to or reduced their stakes in the business. Point72 Asset Management L.P. increased its holdings in shares of Xenon Pharmaceuticals by 177.7% in the fourth quarter. Point72 Asset Management L.P. now owns 2,992,597 shares of the biopharmaceutical company’s stock valued at $93,489,000 after purchasing an additional 1,914,797 shares during the last quarter. Perceptive Advisors LLC grew its stake in shares of Xenon Pharmaceuticals by 19.3% in the fourth quarter. Perceptive Advisors LLC now owns 2,411,447 shares of the biopharmaceutical company’s stock valued at $75,334,000 after acquiring an additional 389,396 shares in the last quarter. Capital World Investors grew its stake in shares of Xenon Pharmaceuticals by 136.1% in the fourth quarter. Capital World Investors now owns 2,274,974 shares of the biopharmaceutical company’s stock valued at $71,070,000 after acquiring an additional 1,311,474 shares in the last quarter. Marshall Wace LLP grew its stake in shares of Xenon Pharmaceuticals by 3,996.8% in the fourth quarter. Marshall Wace LLP now owns 1,220,957 shares of the biopharmaceutical company’s stock valued at $38,143,000 after acquiring an additional 1,191,154 shares in the last quarter. Finally, Suvretta Capital Management LLC grew its stake in shares of Xenon Pharmaceuticals by 95.1% in the third quarter. Suvretta Capital Management LLC now owns 1,158,961 shares of the biopharmaceutical company’s stock valued at $17,709,000 after acquiring an additional 564,850 shares in the last quarter. Hedge funds and other institutional investors own 69.15% of the company’s stock.

Shares of XENE stock opened at $33.77 on Friday. The company’s fifty day simple moving average is $31.33 and its 200-day simple moving average is $29.39. The firm has a market cap of $1.75 billion, a PE ratio of -18.16 and a beta of 1.79. Xenon Pharmaceuticals has a 12 month low of $14.65 and a 12 month high of $36.42.

Xenon Pharmaceuticals Company Profile (Get Rating)

Xenon Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders.

Featured Stories

Get a free copy of the Zacks research report on Xenon Pharmaceuticals (XENE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Xenon Pharmaceuticals (NASDAQ:XENE)

Receive News & Ratings for Xenon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.